EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 704 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Large Study Confirms that HPV Vaccine Prevents Cervical Cancer October 14, 2020 England moves to a single-dose HPV vaccine June 21, 2023 Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 July 9, 2020 Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... November 14, 2025 Load more HOT NEWS FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage... New on NCI’s Websites for December 2021 Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... ESMO Calls for Cancer to Be at the Core of the...
